These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28279968)

  • 1. Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies.
    Armstrong PC; Hoefer T; Knowles RB; Tucker AT; Hayman MA; Ferreira PM; Chan MV; Warner TD
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):949-956. PubMed ID: 28279968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
    Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
    J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
    Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
    J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
    Schneider DJ; Chava S
    Coron Artery Dis; 2016 May; 27(3):185-90. PubMed ID: 26751426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
    Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
    Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
    Baos S; Underwood W; Culliford L; Reeves BC; Rogers CA; Bowles R; Johnson T; Baumbach A; Mumford A
    Trials; 2017 Nov; 18(1):529. PubMed ID: 29121979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
    Thomas MR; Angiolillo DJ; Bonaca MP; Ajjan RA; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Sabatine MS; Storey RF
    Thromb Haemost; 2017 May; 117(5):940-947. PubMed ID: 28300867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
    Storey RF; Bliden KP; Ecob R; Karunakaran A; Butler K; Wei C; Tantry U; Gurbel PA
    J Thromb Haemost; 2011 Sep; 9(9):1730-7. PubMed ID: 21707911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
    Wijeyeratne YD; Joshi R; Heptinstall S
    Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
    Cho JR; Rollini F; Franchi F; DeGroat C; Bhatti M; Dunn EC; Ferrante E; Muniz-Lozano A; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1075-1083. PubMed ID: 26117466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
    Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
    Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study.
    Kardassis D; Egnell AC; Åstrand M; Daniels SJ; Whatling C; Fjellström O; Gabrielsen A
    J Am Heart Assoc; 2024 Jun; 13(11):e033985. PubMed ID: 38804212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
    Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
    J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
    Guo LZ; Kim MH; Jin CD; Lee JY; Yi SJ; Park MK; Cho YR; Park TH
    Platelets; 2015; 26(6):563-9. PubMed ID: 25275429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.
    Angiolillo DJ
    Drugs; 2012 Nov; 72(16):2087-116. PubMed ID: 23083110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.